Patents Examined by Samira J Jean-Louis
  • Patent number: 10842789
    Abstract: The present invention relates to a method of treating schizophrenia in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a selective D3 antagonist, wherein said subject has at least one negative symptom (NS) among the following core negative symptoms in PANSS: Blunted Affect (N1), Emotional Withdrawal (N2), Poor Rapport (N3), Passive withdrawal (N4), and Lack of Spontaneity (N6); with moderate or higher severity. Methods for improving the probability of success and/or the effect of a treatment of schizophrenia in a subject in need thereof are also described.
    Type: Grant
    Filed: November 5, 2018
    Date of Patent: November 24, 2020
    Assignee: PIERRE FABRE MEDICAMENT
    Inventors: Fran├žoise Tonner, Armida Mucci
  • Patent number: 10828315
    Abstract: The present invention provides pharmacological compounds including an effector moiety conjugated to a binding moiety that directs the effector moiety to a biological target of interest. Likewise, the present invention provides compositions, kits, and methods (e.g., therapeutic, diagnostic, and imaging) including the compounds. The compounds can be described as a protein interacting binding moiety-drug conjugate (SDC-TRAP) compounds, which include a protein interacting binding moiety and an effector moiety. For example, in certain embodiments directed to treating cancer, the SDC-TRAP can include an Hsp90 inhibitor conjugated to a cytotoxic agent as the effector moiety.
    Type: Grant
    Filed: March 8, 2016
    Date of Patent: November 10, 2020
    Assignee: MADRIGAL PHARMACEUTICALS, INC.
    Inventors: Dinesh U. Chimmanamada, Weiwen Ying, Junyi Zhang, Teresa Kowalczyk-Przewloka, Jun Jiang, Sami Osman, Genliang Lu, Dharma Vutukuri, James Loch, Shoujun Chen
  • Patent number: 10813906
    Abstract: Disclosed herein is a method for treating infection by an enteropathogen and/or enhancing growth performance, which includes administering to a subject in need thereof a composition containing a ferrous amino acid chelate. Also disclosed herein is an animal feed containing the ferrous amino acid chelate.
    Type: Grant
    Filed: December 20, 2018
    Date of Patent: October 27, 2020
    Assignee: PROFEAT BIOTECHNOLOGY CO., LTD.
    Inventors: Tsun-Yuan Lin, Mu-Kuei Chen, Kai-Ting Wang, Hsun-Jin Jan
  • Patent number: 10806712
    Abstract: The present invention concerns compounds, compositions containing these compounds, and methods of using these compounds and compositions as inhibitors of Stat3 signaling, Stat3 dimerization, Stat3-DNA binding, Stat5-DNA binding, and/or aberrant cell growth in vitro or in vivo, e.g., as anti-cancer agents for treatment of cancer, such as breast cancer. The compounds of the invention include, but are not limited to, NSC 74859 (S3I-201), NSC 42067, NSC 59263, NSC 75912, NSC 11421, NSC 91529, NSC 263435, and pharmaceutically acceptable salts and analogs of the foregoing. Other non-malignant diseases characterized by proliferation of cells that may be treated using the compounds of the invention, but are not limited to, cirrhosis of the liver; graft rejection; restenosis; and disorders characterized by a proliferation of T cells such as autoimmune diseases, e.g., type 1 diabetes, lupus and multiple sclerosis.
    Type: Grant
    Filed: March 11, 2019
    Date of Patent: October 20, 2020
    Assignees: H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC., UNIVERSITY OF SOUTH FLORIDA, UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC.
    Inventors: James Turkson, Said M. Sebti, Wayne Guida, Man Lun Yip, Nicholas Lawrence, Harshani Rithma Lawrence, Benjamin Greedy
  • Patent number: 10792290
    Abstract: An implant comprising testosterone or an ester thereof and an aromatase inhibitor; the aromatase inhibitor may be selected from the group consisting of anastrozole, letrozole, and exemestane. In one embodiment the implant is a sustained release, subcutaneous implant. Also disclosed are therapies for patients with symptoms of relative androgen deficiency, breast cancer survivors and other therapies in which testosterone is indicated but elevated estradiol levels are avoided.
    Type: Grant
    Filed: August 23, 2018
    Date of Patent: October 6, 2020
    Assignee: SUNNYBROOK PHARM, LLC
    Inventor: Rebecca L. Glaser
  • Patent number: 10776461
    Abstract: Peroxisome proliferator activated receptor (PPAR) compounds, and methods of using the same for treating bone fractures, treating osteoporosis and/or metabolic bone diseases, and inducing osteogenesis and/or chondrogenesis, are disclosed.
    Type: Grant
    Filed: January 14, 2019
    Date of Patent: September 15, 2020
    Assignee: The University of Toledo
    Inventors: Bruce E. Heck, Dong Hyun Kim, Paul W. Erhardt, Brian J. Kress
  • Patent number: 10759758
    Abstract: The present invention relates to crystalline forms of N-{6-(2-Hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2H-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide, to processes for their preparation, to pharmaceutical compositions comprising them and to their use in the control of disorders.
    Type: Grant
    Filed: April 25, 2017
    Date of Patent: September 1, 2020
    Assignee: Bayer Pharma Aktiengesellschaft
    Inventors: Tobias Thaler, Johannes Platzek, Nicolas Guimond
  • Patent number: 10758535
    Abstract: The present invention provides a therapeutic drug that is useful for levodopa induced dyskinesia in Parkinson's disease. In particular, the present invention provides a composition and method for treating, improving, suppressing the progression, or preventing motor complications associated with levodopa therapy for Parkinson's disease, especially levodopa induced dyskinesia (PD-LID), comprising tandospirone or a pharmaceutically acceptable salt or prodrug thereof, wherein the tandospirone or a pharmaceutically acceptable salt or prodrug thereof is parenterally administered.
    Type: Grant
    Filed: April 26, 2019
    Date of Patent: September 1, 2020
    Assignee: SUMITOMO DAINIPPON PHARMA CO., LTD.
    Inventors: Mitsumasa Kurita, Yuki Ikeda, Mitsuhiro Nakato
  • Patent number: 10758541
    Abstract: This application relates to methods of treating and/or preventing cancer (e.g., non-small cell lung cancer, renal cell carcinoma, hepatocellular carcinoma, thyroid carcinoma, colorectal cancer, gastrointestinal stromal tumors, breast cancer, prostate cancer, pancreatic cancer, or thymoma) in patients in need thereof comprising administering to the patient a therapeutically effective amount of a CDK inhibitor (e.g., milciclib) in combination with a therapeutically effective amount of another anticancer drug (e.g., sorafenib, lenvatinib, regorafenib, sunitinib, nivolumab, gemcitabine, and palbociclib).
    Type: Grant
    Filed: November 6, 2018
    Date of Patent: September 1, 2020
    Assignee: Tiziana Life Sciences PLC
    Inventor: Kunwar Shailubhai
  • Patent number: 10751333
    Abstract: Disclosed herein are liquid diluents, formulations, and kits for preparing reconstituted suspensions of a proton pump inhibitor (e.g., omeprazole). The present disclosure also provides formulations for liquid diluents that do not have a tendency for gel formation following exposure to freeze-thaw cycles.
    Type: Grant
    Filed: July 16, 2019
    Date of Patent: August 25, 2020
    Assignee: CUTISPHARMA, INC.
    Inventors: Zeus Pendon, Steven Dinh
  • Patent number: 10730879
    Abstract: Polymorphs of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one, compositions thereof, methods for their preparation, and methods for their use are disclosed.
    Type: Grant
    Filed: September 6, 2016
    Date of Patent: August 4, 2020
    Assignee: Gilead Calistoga LLC
    Inventors: Ernest Carra, Michael Gerber, Bing Shi, Keiko Sujino, Duong Tran, Fang Wang, Jerry B. Evarts
  • Patent number: 10722478
    Abstract: The present invention relates to methods for the treatment or prevention of fatigue associated with disordered sleep, for example, in multiple sclerosis, fibromyalgia, Fabry's disease, Parkinson's disease, or traumatic brain injury, using cyclobenzaprine. The present invention further relates to a biomarker for the therapeutic effects of a cyclobenzaprine treatment.
    Type: Grant
    Filed: August 9, 2019
    Date of Patent: July 28, 2020
    Assignee: Tonix Pharma Holdings Limited
    Inventors: Seth Lederman, Herb Harris
  • Patent number: 10722488
    Abstract: The compositions of the various embodiments include benzoyl peroxide and Hest G-18-0. The methods of this invention include treating acne, increasing the solubility of benzoyl peroxide, and treating the skin. Embodiments are also directed to a dual chamber package comprising a chamber for benzoyl peroxide and a chamber for Hest G-18-0.
    Type: Grant
    Filed: June 7, 2017
    Date of Patent: July 28, 2020
    Assignee: RODAN & FIELDS, LLC
    Inventors: Kathy Ann Fields, Kathryn Pregerson Rodan, George Paul Majewski, Timothy John Falla, Dzung Q. Le
  • Patent number: 10716774
    Abstract: Isotretinoin compositions having improved bioavailability are disclosed. The compositions are oral formulations containing isotretinoin, a lipid excipient and a cosolvent, wherein the ratio of isotretinoin to the lipid excipient is from about 1:1.2 to about 1:1.6. The compositions can be in the form of a pharmaceutically acceptable oral dosage form such as a capsule or compressed tablet wherein the isotretinoin is adsorbed onto blended particles of a cellulosic polymer and silicon dioxide in combination with a lipid excipient such as soy phosphatidylcholine and a cosolvent such as propylene glycol. Methods of preparing the compositions and methods of treatment using the compositions are also disclosed.
    Type: Grant
    Filed: January 3, 2019
    Date of Patent: July 21, 2020
    Assignee: YALE PHARMACEUTICALS LLC
    Inventor: Basavaraj Siddalingappa
  • Patent number: 10717764
    Abstract: Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.
    Type: Grant
    Filed: May 31, 2019
    Date of Patent: July 21, 2020
    Assignee: Agios Pharmaceuticals, Inc.
    Inventors: Janeta Popovici-Muller, Rene M. Lemieux, Jeremy Travins, Zhenwei Cai, Dawei Cui, Ding Zhou
  • Patent number: 10717746
    Abstract: Provided are a series of novel pyridine or pyrimidine derivatives which inhibit CDK9 and may be useful for the treatment of hyperproliferative diseases. In particular the compounds are of use in the treatment of proliferative disease such as cancer including hematological malignancies such as acute myeloid leukemia, multiple myeloma, chronic lymphocytic leukemia, diffuse large B cell lymphoma, Burkitt's lymphoma, follicular lymphoma and solid tumors such as breast cancer, lung cancer, neuroblastoma and colon cancer.
    Type: Grant
    Filed: December 6, 2017
    Date of Patent: July 21, 2020
    Assignee: ASTRAZENECA AB
    Inventors: Bernard Barlaam, Christopher De Savi, Janet Hawkins, Alexander Hird, Michelle Lamb, Kurt Pike, Melissa Vasbinder
  • Patent number: 10709711
    Abstract: This invention is in the area of improved compounds and methods for treating selected cancers and hyperproliferative disorders.
    Type: Grant
    Filed: December 20, 2018
    Date of Patent: July 14, 2020
    Assignee: G1 Therapeutics, Inc.
    Inventors: Jay Copeland Strum, John Emerson Bisi, Patrick Joseph Roberts, Francis Xavier Tavares
  • Patent number: 10702537
    Abstract: A method of treating a condition of in a human patient comprising pharmacologically activating a translocator protein of 18 kDa (TSPO), wherein the condition is one of a chronic methamphetamine addiction, a medical consequence of methamphetamine use; a behavioral consequence of methamphetamine use, an HIV associated cognitive motor disorder, an HIV-associated neurodegenerative disorder, and a neuroinflammatory response.
    Type: Grant
    Filed: June 4, 2018
    Date of Patent: July 7, 2020
    Assignee: BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY and Agricultural and Mechanical College
    Inventors: Nicholas E. Goeders, Christopher Dalton Schmoutz
  • Patent number: 10696652
    Abstract: A method of treating a mammal suffering from a cancer responsive to inhibition of protein kinase activity, by administering to the mammal an amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, effective to inhibit protein kinase activity, wherein the compound of formula (I) is:
    Type: Grant
    Filed: April 25, 2018
    Date of Patent: June 30, 2020
    Assignee: Vernalis (R&D) Ltd.
    Inventors: Stephen Stokes, Nicolas Foloppe, Andrea Fiumana, Martin Drysdale, Simon Bedford, Paul Webb
  • Patent number: 10688093
    Abstract: The present invention provides methods for inhibiting Fyn kinase, using 5-3-pyridin-2-amine, 6-3-imidazo[1,2-a] pyrazine, 6-3-imidazo[1,2-b] pyridazine, N-(5-imidazo [2,1-b][1,3,4] thiadiazol-2-yl)-amine, 4-3-1H-pyrazolo[3,4-b] pyridine, and N-(3-imidazo [1,2-b] pyridazin-6-yl) amine compounds and methods of treatment, prevention, inhibition or amelioration of diseases and conditions associated with Fyn kinase using such compounds.
    Type: Grant
    Filed: September 8, 2016
    Date of Patent: June 23, 2020
    Inventor: Warren C. Lau